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ABSTRACT Recurrent vulvovaginal candidiasis (RVVC) is a widespread chronic infec-
tion that has a substantial negative impact on work and quality of life. The develop-
ment of antimicrobial resistance and biofilm formation are speculated to contribute
to Candida pathogenicity and treatment ineffectiveness. Designed antimicrobial pep-
tides (dAMPs) are chemically modified from endogenous antimicrobial peptides that
provide the first line of defense against pathogens. The goal here is to identify a
dAMP for the topical treatment of RVVC. The dAMP MICs were determined for 46
fluconazole-susceptible and fluconazole-resistant Candida spp. clinical isolates. The
possibility of inducing dAMP drug resistance and comparison of dAMP and flucona-
zole activity against preformed Candida biofilm and biofilm formation were evalu-
ated. Assessment of mammalian cell viability was determined using bioluminescent
human keratinocytes. The dAMP effect on fungus was probed via scanning electron
microscopy, and topically applied dAMP activity was evaluated in a rodent vulvovagi-
nal candidiasis (VVC) infection model. dAMPs demonstrated broad-spectrum antimi-
crobial activity against common causative clinical Candida isolates, reduced pre-
formed biofilm, and inhibited biofilm formation. An evaluated dAMP did not induce
resistance after repeated exposure of Candida tropicalis. The dAMPs were selective
for Candida cells with limited mammalian cytotoxicity with substantial activity in a
rodent VVC model. dAMPs are described as having potent antifungal and antibiofilm
activity, likely direct membrane action with selectivity for Candida cells, with limited
resistance development. Combined with activity in a rodent VVC model, the data
support clinical evaluation of dAMPs for topical treatment of VCC and recurrent VVC
infections.
KEYWORDS antimicrobial peptides, antifungals, vulvovaginal candidiasis, biofilm,
antifungal activity, fungicidal activity
Recurrent vulvovaginal candidiasis (RVVC), defined as four or more vulvovaginalcandidiasis (VVC) infections per year, is a widespread chronic, often drug-resistant
mucosal infection that has a substantial negative impact on work and quality of life
(1–3) and annually affects approximately 138 million women worldwide (4, 5). RVVC
infection is caused by Candida albicans and non-albicans Candida species (4). VVC and
RVVC are often treated with azole agents that are fungistatic due to inhibition of
ergosterol biosynthesis in Candida spp. (6); however, they are substantially less active
against non-albicans Candida spp. (2, 7).
For RVVC treatment, the Infectious Diseases Society of America guidelines recom-
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mend a long-term off-label suppressive treatment regimen with oral fluconazole for at
least 6 months (8); however, recurrence rates of 60% to 70% are observed (9, 10). There
are no products currently approved for the treatment of RVVC. Additionally, most
infections occur in women of childbearing potential. The FDA, due to teratogenicity
concerns (11), has advised against prescribing oral fluconazole for VCC treatment
during pregnancy.
The development and spread of antimicrobial resistance and the shift in yeast
epidemiology, from C. albicans to non-albicans Candida spp., including Candida
glabrata, Candida dubliniensis, Candida lusitaniae, Candida tropicalis, Candida krusei,
Candida kefyr, and Candida parapsilosis, have been driven by chronic use of over-the-
counter azoles (4, 12). Furthermore, to exacerbate RVVC recalcitrance, Candida could
form drug-resistant biofilm (4, 13, 14). Fungal biofilms are complex colonies of micro-
organisms encased in a dense extracellular matrix comprised of proteins, polysaccha-
rides, and carbohydrates, thereby providing protection from the host’s immune system
and antifungal agents (15, 16). For RVVC, innovation in antifungal treatment is needed
due to the rapid emergence of fungal resistance, a recent shift in increased epidemi-
ologic prevalence of fluconazole-resistant non-albicans species, and the possible diffi-
culty of treating biofilms.
Designed antimicrobial peptides (dAMPs) are laboratory-synthesized peptides that
have been rationally designed from naturally occurring antimicrobial peptides (AMPs)
that provide defense against invading pathogens (17). AMPs have direct antipatho-
genic activities and kill fungi as well as both Gram-negative and Gram-positive bacteria
(18–20). An important action of AMPs is direct membranolytic electrostatic perturbation
of the barrier function of the pathogen’s membrane (21), with cell selectivity increased
by the presence of ergosterol, a membrane lipid found in fungi (22). Moreover, this
remarkable targeting and direct contact disruption of the pathogen’s membrane makes
resistance less likely to develop (18), an integral feature for fighting antimycotic-
resistant infections. Four dAMPs rationally derived from tachyplesin I, a disulfide
-sheet antimicrobial peptide, from the horseshoe crab (Tachypleus tridentatus), were
evaluated for their potential utility to topically treat RVVC.
RESULTS
In vitro antifungal activity. The dAMPs (Table 1) exhibited broad-spectrum anti-
microbial activity against Candida strains (Table 2), including against the intrinsically
fluconazole-resistant C. krusei. The MICs of fluconazole-susceptible and resistant C.
albicans and C. glabrata and resistant C. krusei and C. parapsilosis were 16 to 32 g/ml
corresponding to 6.5 to 17 M, though a minority of the total tested for RP556
resulted in an MIC of 8 g/ml (3.7 M). In contrast, the dAMP MICs of fluconazole-
susceptible and resistant C. tropicalis, susceptible C. parapsilosis, C. kefyr, C. lusitaniae, C.
dubliniensis, Candida sphaerica, and Candida famata were largely 2 to 8 g/ml (0.81 to
4.3 M). In the fluconazole-resistant strains, the dAMPs were more effective than
fluconazole, based on M levels, in all of the Candida spp. tested. In terms of a
microgram per milliliter comparison, fluconazole was more effective in only C. albicans
and C. parapsilosis.
Minimum fungicidal concentrations (MFCs) were determined on 9 isolates, repre-
sentatives of selected groups as listed in Materials and Methods, each tested against all
4 dAMPs (total, 36 assays). In 14 of the 36 assays, the MFC was the same as the MIC or
slightly higher. In 3 assays, the MFC was 2 tube dilutions higher than the MIC. In 4
TABLE 1 dAMPs evaluated in support of RVVC treatment evaluation
Peptide Amino acid sequence Length (aa)a
RP504 FOIOAOLGGCLGOFCGGIOAOLOF-NH2; disulfide bridge: C10–C15 24
RP554 FOLOAOIOVOLOAOIOL-NH2 17
RP556 RWCFKVCYKGICYKKCK-NH2; disulfide bridge: C3–C16, C7–C12 17
RP557 RFCWKVCYKGICFKKCK-NH2; disulfide bridge: C3–C16, C7–C12 17
aaa, amino acids.
Woodburn et al. Antimicrobial Agents and Chemotherapy
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assays, the MICs ranged from 4 to 16 g/ml, with MFCs of 32 g/ml. In 7 assays, the
MIC was 32 g/ml, and the MFC was 32 g/ml. In 8 assays, the MFC/MIC ratio could
not be determined, as the MIC was 32 g/ml. Thus, most commonly, the MIC and
MFC values of the dAMPs were near to each other in value, suggesting that the
inhibiting mechanism is commonly a lethal event, and showed fungicidal activity for
the dAMPs.
Classically, fluconazole is regarded as only a fungistatic agent, and this was con-
firmed with C. albicans (17-88), where the MIC was 1 g/ml (3.27 M) and the MFC was
64 g/ml (209 M). This contrast, with a lack of fluconazole fungicidal activity, was
striking. Because of the frequent similarity of dAMP MIC and MFC with representatives
of the selected groups (detailed in Materials and Methods), it was of interest then to
similarly study fluconazole further. Clinical isolates sent to the California Institute for
Medical Research (CIMR) reference laboratory were assayed. Eleven of 11 C. albicans
isolates had MFCs 4-fold and up to 64 fold greater than MICs.
Candida did not develop resistance, under the specific experimental conditions
used, against RP554, RP556, and RP557. The starting MICs and MFCs, before the
serial passages in increasing concentrations, for RP556, RP557, RP554 were 2, 4, and
4 g/ml and 2, 4, and 8 g/ml, respectively. When the passage level of 16 g/ml was
reached, none of the dAMP-passaged C. tropicalis isolates survived for further study.
Thus, survivors at the lower level of 8 g/ml were tested, and the MICs and MFCs for
RP556, RP557, RP554 were 2, 4, and 4 g/ml (0.93, 1.9, 2.1 M) and 8, 8, and 8 g/ml
(3.7, 3.7, 4.3 M), respectively. Thus, the MICs for all 3 dAMPs were unchanged by serial
passages at increasing concentrations, and the MFCs were unchanged or slightly
changed. Thus, for none of the dAMPs did serial passages (total, 9 passages in doubly
increasing concentrations) increase the MIC. The concurrent control, passaged 9 times
in the absence of drug, had no changes from the starting MIC and MFC.
Fungal biofilm inhibition. Biofilm formation is a key driver of C. albicans patho-
genicity. The dAMPs were remarkably effective in inhibiting biofilm formation (Table 3)
and preformed C. albicans biofilm (example in Fig. 1 and Table 3). RP557 was quite
potent with 16 g/ml (7.5 M) and 4 g/ml (1.9 M) required to inhibit biofilm forma-
tion and mature biofilm, respectively. Fluconazole was only marginally inhibitory,
even at 64 g/ml (209 M). The order of effectiveness (lowest concentration with a
statistically significant result) on preformed C. albicans biofilm was as follows:
RP557  RP554  RP556  RP504   fluconazole; that for inhibiting biofilm growth
was as follows: RP557  RP554  RP556  RP504   fluconazole (Fig. 1).
The dAMPs inhibited established biofilm. Particularly potent were RP557 and RP554
at concentrations substantially less than those required to inhibit planktonic fungi
(Table 3). Fluconazole was inhibitory at 64 g/ml (209 M) whereas RP557 was quite
potent at 4 g/ml (1.9 M). The preformed biofilm activity quotient (Table 3) was 0.125
and 0.5 for RP557 and RP554, respectively, in comparison to that for fluconazole, which
produced a ratio of 64. The dAMPs were also potent against inhibiting biofilm forma-
tion, with activity quotients of 0.5 and 2 for RP557 and RP554, respectively, in com-
parison to that for fluconazole with a ratio of 64.
Direct cell wall perturbation. Scanning electron microscopy (SEM) on planktonic
and on preformed biofilm C. albicans suggested that dAMP-mediated fungal damage
TABLE 3 Susceptibility of dAMPs and fluconazole against planktonic yeasts, biofilm formation, and preformed biofilm for C. albicans
isolate 17-88









Fluconazole 3.3 [1.0] 209 [64] 64 209 [64] 64
RP504 13 [32] 26 [64] 2 26 [64] 2
RP554 8.5 [16] 17 [32] 2 4.3 [8] 0.5
RP556 7.4 [16] 15 [32] 2 15 [32] 2
RP557 15 [32] 7.5 [16] 0.5 1.9 [4] 0.125
aLowest concentration with statistically significant inhibition.
bRatio of biofilm activity endpoint, statistically significant difference, to MIC.
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was via membrane perturbation. Control planktonic C. albicans appeared as well-
rounded and intact yeasts with prominent bud scars; whereas fluconazole-treated cells
had scattered irregular areas across the cell surface, reflecting some compromised cell
membranes and walls. The membrane surfaces of dAMP-treated planktonic cells, in
contrast, were dramatically irregular and roughened, which increased in severity with
concentration, reflecting increased cell wall damage (cells treated with a representative
dAMP, RP554, are shown in Fig. 2).
In biofilms, fluconazole-treated cells showed only a coating with a film-like or
granular substance, likely residual extracellular matrix. The surfaces of the Candida cells
within the biofilm, containing some pseudohyphal or hyphal cells, became roughened,
corrugated, and flattened upon treatment with RP554, increasing with increasing
concentrations, indicating severe cell wall damage and implying cellular perturbation
via membrane disruption.
Limited cytotoxicity to mammalian cells. AMP development has been hampered
by unwanted toxicity to mammalian cells. The dAMPs evaluated here exhibited varying
FIG 1 dAMPs effectively inhibit fluconazole-resistant C. albicans preformed fungal biofilm. Fluconazole and dAMPs were added to C.
albicans 17-88 preformed biofilm for 24 h, and biofilm inhibition was evaluated via metabolic evaluation using XTT (39). Data represent
the mean  standard deviation (SD) of 3 to 4 measurements, with RP554 and RP557 evaluated in two independent experiments; statistical
significance, compared to control, was determined by one-way ANOVA followed by Dunnett’s test (*, P  0.05; ***, P  0.001; ****,
P  0.0001).
FIG 2 Damage of C. albicans biofilm by RP554. Scanning electron micrographs of C. albicans 17-88 biofilm incubated with test article for 24 h. (A) Control (no
treatment); (B) 64 g/ml fluconazole; (C to E) 16, 32, and 64 g/ml RP554. Rows i to iii represent micrographs captured at 1,000, 5,000, and 10,000
magnification; refer to scale bars for actual size range. The black arrows indicate cell wall indentations and cell membrane damage, and white arrows indicate
surface coating with extracellular matrix residue.
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degrees of cytotoxicity, with RP556 and RP557 exhibiting limited toxicity as demon-
strated by using both a noninvasive continuous bioluminescence assay (Fig. 3) and a
lactate dehydrogenase (LDH) membrane disruption release assay. The results from the
bioluminescence live imaging assays and the LDH assay were similar (not shown). The
10% lethal dose (LD10), which is the concentration required to kill 10% of the human
keratinocytes, determined by bioluminescence live imaging, following 8 h incubation,
for RP504, RP554, RP556, and RP557 was 143, 19, 276, and 287 g/ml, respectively,
correlating to 58, 10, 128, and 134 M.
Treatment results in vivo. The activity of intravaginally (IVG) administered dAMPs
was evaluated in an immunosuppressed rat vulvovaginal candidiasis model. Treatment
was administered IVG twice daily (BID) starting from 48 h after C. albicans infection for
a total of three sequential days. dAMP treatment did not cause any adverse safety
concerns as measured by clinical observations, body weight, and histopathology.
Histologically, there was no damage to the squamous epithelium lining of the treated
vagina. The day 5 CFU results are depicted in Fig. 4. The topical application of 2%
RP504, RP554, or RP557 resulted in significant reductions in fungal counts relative to
the control group in a rodent VVC model (Fig. 4 [all P  0.0001]), with RP557 being the
most potent. The positive control, 2% miconazole, caused a near 4-log reduction in
fungal counts, compared to the concurrent control group (P  0.0001). There was no
difference in activity between 2% RP557 and 2% miconazole. All evaluated doses of
RP557, 0.2, 1, or 2%, caused marked reductions in vulvovaginal candidiasis, with 2%
causing the greatest reduction.
DISCUSSION
The increase in RVVC infections has generated an urgent need for new antifungal
agents with novel mechanisms of action that are active against antimycotic-resistant
Candida and recalcitrant biofilm with a limited likelihood of developing resistance.
Designed antimicrobial peptides (dAMPs) are engineered analogs of naturally occurring
FIG 3 RP556 and RP557 exhibit minimal mammalian cell toxicity. Cellular toxicity was noninvasively assayed using
bioluminescent human keratinocytes and viability was assayed using an IVIS Lumina imaging system. Cells were
plated at 1  104 cells/well, adhered overnight, dAMPs added, and bioluminescence evaluated over 8 h. Concen-
trations were performed in triplicate, and data is from two independent experiments.
Woodburn et al. Antimicrobial Agents and Chemotherapy












































AMPs that are ubiquitous in nature and provide the first line of defense against
invading pathogens.
The dAMPs (RP504, RP544, RP556, and RP557) exhibited broad-spectrum antifungal
activity against 46 clinical isolates comprising fluconazole-sensitive and resistant strains
of C. albicans, C. glabrata, C. tropicalis, and C. parapsilosis and intrinsically resistant C.
krusei. The dAMPs are commonly fungicidal, as MIC values were similar to MFCs, in
contrast to fluconazole which is fungistatic (8). To confirm the mechanism of action via
direct membrane perturbation, electron microscopy performed on both planktonic and
biofilm C. albicans was consistent with dAMP-mediated fungal effects via membrane
perturbation, whereas fluconazole appeared only fungistatic.
AMPs are part of the innate immune response (23). Although there is extensive
evidence for AMP actions at microbial membranes, and they bind to membrane sterols
(22), there is also evidence that AMPs can bind to target ribosomal subunits; can inhibit
synthesis of DNA, RNA, proteins, and macromolecules; and can inhibit respiration,
intracellular protein folding, and iron regulation (24–26). These intracellular actions may
be relevant to antifungal action, as AMP penetration into fungal cells by many different
mechanisms has been shown (27). Particularly relevant to the antifungal actions that we
demonstrate in our studies, AMPs have also been shown to bind cell wall glucan and
thus possibly interfere with cell wall synthesis (28). At the host level, AMPs can act as
signaling molecules and immune regulators (23). The myriad of actions described may
be alternative antifungal actions to a membrane-active dAMP property or augment it.
Biofilm has been debated to be a critical component of RVVC pathogenicity and
recalcitrance (4, 14, 28–30, 43). Biofilms are intrinsically resistant to currently approved
antifungal treatment, and compared to planktonic cells, usually require drug concen-
trations many-fold the corresponding MIC values for biofilm eradication (31). In con-
trast, the dAMPs exhibited the ability to affect biofilm at concentrations far less than
those required for planktonic isolates, particularly RP554 and RP557 with preformed
biofilm activity quotients of 0.125 and 0.5, respectively. A similar phenomenon has
been observed with the naturally occurring AMP LL-37 on Pseudomonas aeruginosa
biofilms. LL-37 was found to affect biofilm formation by inhibiting bacterial cell
attachment, stimulating twitching motility, and affecting two quorum sensing systems,
thereby downregulating genes necessary for biofilm growth (32). A possible limitation
of the biofilm studies is that yeast cells could potentially have left the biofilm or been
removed from the biofilm during the procedures and that these planktonic yeast cells
may have had a different susceptibility than the remaining adherent cells.
FIG 4 dAMP topical treatment reduces vulvovaginal candidiasis in a rodent model. Effects of miconazole
(2%, n  10), RP504 (2%, n  5), RP554 (2%, n  5), and RP557 (0.2%, n  5; 1%, n  5; 2%, n  10) were
evaluated and compared to those of the controls (n  10). The C. albicans (ATCC 44858) vaginal infection
model involved oophorohysterectomized Wistar rats with CFU evaluated at day 5. On day 0, the animals
were inoculated IVG with C. albicans at 1.5  107 CFU/rat (0.1 ml/rat). dAMPs and miconazole were
administered IVG at 0.1 ml/rat BID at 8-h intervals starting from 48 h after infection for a total of three
sequential days. CFU were evaluated on day 5 with the limit of detection (LOD, dashed lines) being 0.7
CFU/rat. Data represent mean  standard error (SE) with significant difference defined as P  0.0001
(****) compared to that of the control as determined by one-way ANOVA followed by Dunnett’s test.
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An efficacious antifungal must be able to affect fungi and not host cells, thereby
decreasing off-target safety concerns. The development of a clinically viable AMP has
previously been hampered by unwanted toxicity to mammalian host cells at therapeu-
tic doses (33); therefore, the cytotoxicity of dAMPs was evaluated using human kera-
tinocytes transfected with a bioluminescent reporter gene to enable real-time assess-
ment of mammalian cell viability. RP556 and RP557 exhibited limited toxicity with LD10
concentrations of 276 and 287 g/ml (128 and 134 M) following 8 h incubation,
followed by RP554 and RP504 at 143 and 19 g/ml (58 and 10 M), respectively. The
amounts of dAMP required to kill 10% of keratinocytes was orders of magnitude higher
than that needed to inhibit Candida in both planktonic and biofilm forms.
The topical application of dAMPs was effective in reducing C. albicans in a rodent
VVC model. The efficacy of intravaginally administered RP504, RP554, and RP557 was
compared to miconazole and vehicle control in an immunosuppressed rat VVC rodent
model. A recent study indicated oral fluconazole to be ineffective in this model (34).
RP557 was more effective than RP554 and RP504; however, there was no difference in
activity between RP557 and miconazole. It could be clinically more beneficial to
prescribe RP557 over miconazole for RVVC, as resistance rates to miconazole have
increased from 2.4% in 2006 to 59.8% in 2013 for C. albicans (35). Among non-albicans
species, miconazole was resistant against 25.6% and 73.1% of C. glabrata and C. krusei
species, respectively. As RP557 yielded the best Candida cell specificity over mammalian
cells, was potent in both preformed and formed biofilm, and was active in the first VVC
study, it was chosen to undergo an in vivo dose-response evaluation. An increasing
dose-dependent reduction in fungal burden occurred, with 2% RP557 yielding a
statistically significant reduction (P  0.0001) compared to that of the respective vehi-
cle control. Miconazole (2%) and 2% RP557 generated similar activity, with the results
of both antimicrobials consistent with the first study.
Based on the initial encouraging antimicrobial results observed in planktonic iso-
lates and biofilm cultures for Candida and in vivo antimicrobial activity following topical
application in a rodent vaginal candidiasis model, we believe that dAMPs are potential
therapeutic agents for the treatment of RVVC infections and have less susceptibility for
developing microbial resistance. Further studies will also be undertaken to investigate
potential immunomodulatory, resident bacterial microflora and both long-term safety
and therapeutic effects of RP557 treatment. Preclinical development is under way to
evaluate RP557 as a potential therapeutic for the treatment of vulvovaginal candidiasis.
MATERIALS AND METHODS
Peptides. Four dAMPs, whose amino acid sequences are depicted in Table 1, were synthesized by
AmbioPharm (North Augusta, SC) using a synthetic, solid-phase peptide synthesis scheme. Peptide purity
was 96% as assayed by high-performance liquid chromatography/mass spectroscopy. The dAMPs
evaluated here were rationally designed from tachyplesin, a disulfide -sheet antimicrobial peptide
found in hemocytes of the horseshoe crab (Tachypleus tridentatus) (36). Iterative structure activity
modifications to the peptide sequences included amidation of the C terminus, use of non-natural amino
acids with replacement of lysine by ornithine, and optimization of charge density and hydrophobicity.
Source of Candida isolates. Candida clinical isolates were obtained from the California Institute for
Medical Research (CIMR), San Jose, CA. The isolates selected for dAMP evaluation included C. albicans
(5/10), C. glabrata (5/4), C. tropicalis (5/2), C. parapsilosis (5/1), and C. krusei (0/3), with the fractions given
representing susceptible (S) and resistant (R) (S/R), responses to fluconazole, as defined by CLSI criteria
(37). Other Candida clinical isolates were tested against fluconazole for comparative purposes. C. albicans
(ATCC 44858) for the rat vaginal candidiasis assay was obtained from the American Type Culture
Collection (Rockville, MD, USA).
MIC and MFC determination. Inhibition of planktonic growth (MIC) was assessed for the 46 clinical
isolates by the broth macrodilution method in RPMI 1640 using the Clinical and Laboratory Standards
Institute (CLSI) methodology (37), with breakpoints used for fluconazole as per CLSI. The range of
concentrations tested included 0.5 to 32 g/ml comprising 2-fold serial dilutions.
The minimum fungicidal concentration (MFC) was evaluated for all 4 dAMPs on a fluconazole-
susceptible and a fluconazole-resistant strain of C. albicans, C. glabrata, C. tropicalis, and C. parapsilosis,
and a resistant C. krusei, for a total of 9 isolates. These isolates were randomly selected within each of
those groups. Evaluations were performed by subculturing aliquots immediately following determination
of the MIC and defined as killing of 96% of inoculum (38).
Induction of resistance. The long-term effects of RP554, RP556, and RP557 were evaluated on
planktonic growth of C. tropicalis 17-25 by stepwise exposure to increased dAMP concentrations. Inocula
Woodburn et al. Antimicrobial Agents and Chemotherapy












































of 5  102 cells/ml were incubated in the presence of each dAMP for a minimum of 48 h or for the time
necessary for the fungus to reach half the density of an untreated concurrent control or a maximum of
7 days (whichever was longer). The rationale behind the necessity to increase the time between passages
is in order to collect a sufficient inoculum for the next passage as the population decreases in successive
passages owing to drug action. At dAMP concentrations where the fungus was so inhibited that it did
not reach the density described after 7 days of cultivation, the described inoculum was passed from the
drug-containing tube to the next higher dAMP concentration, as well as to a control tube not containing
the drug. Once the fungus reached, in a peptide concentration, the density described, an inoculum was
prepared and passed to a 2-fold higher drug concentration as well as to a control tube not containing
dAMP. This exercise was performed over a 2-fold range of concentrations from 0.06 to 32 g/ml.
Biofilm inhibition. Candida albicans 17-88, 5  105 cell/ml, was allowed to form biofilm for 16 h,
washed three times with 200 l phosphate-buffered saline (PBS), and subsequently challenged imme-
diately or following 24 h with the test articles to assess effects on biofilm formation or preformed biofilm
inhibition, respectively (39). The dAMPs or fluconazole were diluted in RPMI 1640 with a final well
concentration of 64, 32, 16, or 8 g/ml and compared to control wells containing only RPMI. Each
condition contained 3 replicates. Following a total incubation time of 40 h, the wells were washed three
times with 200 l PBS, and then 200 l XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-
5-carboxanilide salt) and menadione solution were added to each well. The plates were incubated at
37°C for 2 h and absorbance read, and data presented, at 490 nm for assessment of inhibition of
metabolism. The endpoint was a statistically significant reduction compared to an untreated concurrent
control.
Scanning electron microscopy. Planktonic C. albicans isolates were morphologically evaluated
following treatment at a drug concentration equal to their MIC level. Established (preformed) C. albicans
biofilm was evaluated following a 24-h incubation with 8, 16, 32, or 64 g/ml of agents. Samples were
processed for scanning electron microscopy as previously described (39, 40). In brief, C. albicans biofilm
samples were cultured on 8-well chamber slides and treated with fluconazole (32 g/ml) and RP554 (16,
32, and 64 g/ml) as described above before being fixed and processed for SEM (40). Planktonic samples
were treated with fluconazole (1 g/ml) and RP554 (16 g/ml) to approximate their respective drug
inhibitory concentrations before being lightly pelleted and fixed similarly in 4% paraformaldehyde with
2% glutaraldehyde in 0.1 M sodium cacodylate buffer. Aliquots (100 l) of yeast suspension were allowed
to settle onto poly-L-lysine-coated coverslips for 12 min before osmium tetroxide postfixation, dehydra-
tion, and hexamethyldisilazane treatment as described for biofilm samples. After mounting onto alumi-
num stubs and gold coating using an Edwards S150A sputter coater to enhance conductivity, samples
were visualized with a Zeiss Merlin field emission scanning electron microscope (Carl Zeiss Microscopy,
Germany) using 3 kV accelerating voltage, 90 to 100 pA probe current, and both InLens secondary
electron and secondary electron 2 detection. Images were captured in TIFF files using a pixel averaging
noise reduction algorithm and 2,048 by 1,536 pixel store resolution. Evaluations were performed in
duplicate.
Bioluminescent human keratinocytes mammalian cytotoxicity. Noninvasive and real-time mon-
itoring of dAMP mammalian cell toxicity was performed using bioluminescent human keratinocytes. A
luciferase stably expressed human keratinocyte (HaCaT; AddexBio Technologies, Inc., San Diego, CA) cell
line was created by transfection with a luciferase gene (RediFect Red-Fluc-Puromycin, catalog number
CL596002; Perkin Elmer, Waltham, MA, USA) (41). The resultant multiplicity of infection was 40:1.
To evaluate mammalian cell viability, the bioluminescent keratinocytes were added, at 104 cells per
well (100 l volume), to black-walled, 96-well plates. Growth medium was supplemented with 150 g/ml
D-luciferin. Plates were incubated overnight at 37°C. dAMPs, formulated in water, were 2-fold serially
diluted from a starting concentration of 2,048 g/ml in growth medium supplemented with 150 g/ml
D-luciferin. The dilution series was performed in triplicate in a separate 96-well plate. The peptide
dilutions, 100 l, were transferred to the keratinocyte plate, resulting in a 200 l total volume. Each dAMP
was studied in triplicate. Results presented are from two independent experiments. Imaging was
performed at 0, 15, and 30 min and then 1, 3, 5, and 8 h after the addition of the dAMP and compared
to concurrently run dAMP-free control wells, using an IVIS Lumina imaging system (Caliper Life Sciences,
Inc., Hopkinton, MA, USA). An exposure time of 1 min, open filter, f-stop 1 was utilized, and data analysis
was performed using the Living Image software program (version 4.3; Caliper Life Sciences, Inc.). To
confirm the cytotoxicity obtained using the bioluminescence assay correlated with a conventional
metabolic release assay, a lactate dehydrogenase (LDH) cell viability assay (LDH-Glo cytotoxicity assay;
Promega) was also utilized. The dAMP concentration required to kill 10% of cells was determined using
GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA).
Animals. All animals received care in compliance with the “Guide for the Care and Use of Laboratory
Animals: Eighth Edition” (National Academies Press, Washington, DC, 2011) in an AAALAC-accredited
ABSL-2 laboratory vivarium.
Rat vulvovaginal candidiasis model. Oophorohysterectomized and immunosuppressed female
Wistar rats were vaginally infected with Candida albicans strain ATCC 44858. Estrogen levels in the rats
were first regulated by subcutaneous (s.c.) administration of estradiol at 10 mg/kg for 3 days before
infection (day 3) and at 4 mg/kg s.c. on day 4. The animals were also immunosuppressed with the
addition of dexamethasone, 2 mg/liter, to the drinking water. Dexamethasone treatment started 3 days
before infection and continued through study termination. On day 0, the animals were inoculated
intravaginally (IVG) with C. albicans at 1.25  107 CFU/rat (0.1 ml/rat). dAMPs, RP554 and RP557, formu-
lated in 2% hydroxypropyl methylcellulose 4000 (HPMC) (Sigma-Aldrich, MA, USA), a semisynthetic, inert,
viscoelastic polymer used extensively as an ophthalmic lubricant, and reference standard mycoderin (2%
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miconazole; Gyno-mycoderin cream, Bowlin, Taiwan) were administered IVG at 0.1 ml/rat twice daily
(BID) at 8-h intervals starting from 48 h after infection (day 2) for a total of three sequential days. Body
weights were taken predose and at termination.
Animals were euthanized on day 5. Vaginal lavage was performed twice with 0.2 ml PBS, and the
lavage fluid was pooled and C. albicans counts, CFU/rat, determined by plating 10-fold dilutions of
samples to Sabouraud agar plates followed by incubation and enumeration. After vaginal lavage fluid
collection, the vaginal tissues were collected from vehicle and the treatment groups, fixed in 10%
formalin, stained with hematoxylin and eosin, and then evaluated (5 sections of vagina in duplicate) by
a board-certified veterinary pathologist.
Statistical analysis. Quantitative data were expressed as mean  standard error or mean  standard
deviation. Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, San Diego, CA,
USA). Unpaired t tests were used to compare differences between two groups. For multiple comparisons,
a one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc analysis was used. Statistical
significance is considered at a P value of 0.05.
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